D R J Arachchillage1, F Kamani2, S Deplano2, W Banya2, M Laffan3. 1. Department of Haematology, Royal Brompton & Harefield NHS Foundation Trust, London, UK; Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, London, UK. Electronic address: d.arachchillage@imperial.ac.uk. 2. Department of Haematology, Royal Brompton & Harefield NHS Foundation Trust, London, UK. 3. Department of Haematology, Imperial College Healthcare NHS Trust and Imperial College London, London, UK.
Abstract
INTRODUCTION: The activated partial thromboplastin time (APTT) is commonly used to monitor unfractionated heparin (UFH) but may not accurately measure the amount of heparin present. The anti-Xa assay is less susceptible to confounding factors and may be a better assay for this purpose. MATERIALS AND METHODS: The validity of the APTT for monitoring UFH was assessed by comparing with an anti-Xa assay on 3543 samples from 475 patients (infants [n=165], children 1-15years [n=60] and adults [n=250]) receiving treatment dose UFH. RESULTS: Overall concordance was poor. The highest concordance (66%; 168/254) was seen in children. Concordance (51.8%) or discordance (48.4%) was almost equal in adult patients. Among adult patients whose anti-Xa level was within 0.3-0.7IU/mL, only 38% had an APTT in the therapeutic range whilst 56% were below and 6% were above therapeutic range. Children and adult patients with anti-Xa of 0.3-0.7IU/mL but sub- therapeutic APTT had significantly higher fibrinogen levels compared to those with therapeutic or supra-therapeutic APTT. CONCLUSIONS: When the anti-Xa level was 0.3-0.7IU/mL, the majority of samples from infants demonstrated a supra-therapeutic APTT, whilst adults tended to have a sub-therapeutic APTT. This may lead to under anticoagulation in infants or over anticoagulation in adults with risk of bleeding if APTT is used to monitor UFH. These results further strengthen existing evidence of the limitation of APTT in monitoring UFH. Discordance of APTT and anti-Xa level in adults and children may be due to elevation of fibrinogen level. Crown
INTRODUCTION: The activated partial thromboplastin time (APTT) is commonly used to monitor unfractionated heparin (UFH) but may not accurately measure the amount of heparin present. The anti-Xa assay is less susceptible to confounding factors and may be a better assay for this purpose. MATERIALS AND METHODS: The validity of the APTT for monitoring UFH was assessed by comparing with an anti-Xa assay on 3543 samples from 475 patients (infants [n=165], children 1-15years [n=60] and adults [n=250]) receiving treatment dose UFH. RESULTS: Overall concordance was poor. The highest concordance (66%; 168/254) was seen in children. Concordance (51.8%) or discordance (48.4%) was almost equal in adult patients. Among adult patients whose anti-Xa level was within 0.3-0.7IU/mL, only 38% had an APTT in the therapeutic range whilst 56% were below and 6% were above therapeutic range. Children and adult patients with anti-Xa of 0.3-0.7IU/mL but sub- therapeutic APTT had significantly higher fibrinogen levels compared to those with therapeutic or supra-therapeutic APTT. CONCLUSIONS: When the anti-Xa level was 0.3-0.7IU/mL, the majority of samples from infants demonstrated a supra-therapeutic APTT, whilst adults tended to have a sub-therapeutic APTT. This may lead to under anticoagulation in infants or over anticoagulation in adults with risk of bleeding if APTT is used to monitor UFH. These results further strengthen existing evidence of the limitation of APTT in monitoring UFH. Discordance of APTT and anti-Xa level in adults and children may be due to elevation of fibrinogen level. Crown
Authors: James W Schurr; Anne-Marie Muske; Craig A Stevens; Sarah E Culbreth; Katelyn W Sylvester; Jean M Connors Journal: Clin Appl Thromb Hemost Date: 2019 Jan-Dec Impact factor: 2.389
Authors: Benjamin Lardinois; Michaël Hardy; Isabelle Michaux; Geoffrey Horlait; Thomas Rotens; Hugues Jacqmin; Sarah Lessire; Pierre Bulpa; Alain Dive; François Mullier Journal: J Clin Med Date: 2022-02-28 Impact factor: 4.241
Authors: D White; S MacDonald; T Bull; M Hayman; R de Monteverde-Robb; D Sapsford; A Lavinio; J Varley; A Johnston; M Besser; W Thomas Journal: J Thromb Thrombolysis Date: 2020-08 Impact factor: 5.221
Authors: Deepa J Arachchillage; Christopher Remmington; Alex Rosenberg; Tina Xu; Maurizio Passariello; Donna Hall; Mike Laffan; Brijesh V Patel Journal: Br J Haematol Date: 2020-06-30 Impact factor: 8.615